UroToday2d
SCS AUA 2024: Financial Toxicity in Testicular Cancer Treatment, Validated Questionnaire Correlated Software Cost Modeling
(UroToday.com) The 2024 South Central AUA annual meeting included a session on lower genitourinary tract cancer, featuring a presentation by Dr. Peter Sullivan discussing financial toxicity in ...
UroToday2d
ESMO 2024: Prostate Cancer Working Group 4 Preliminary Criteria Using Serial PSMA PET/CT for Response Evaluation: Analysis from the PRINCE Trial
(UroToday.com) The 2024 ESMO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Michael Hofman discussing Prostate Cancer Working Group 4 (PCWG4) preliminary ...
UroToday3d
SCS AUA 2024: Indications and Outcomes for Ablation Therapy in Renal Masses
(UroToday.com) The 2024 South Central AUA annual meeting included a session on kidney cancer, featuring a presentation by Dr. Kelly Bree discussing indications and outcomes for ablation therapy in ...
UroToday3d
SCS AUA 2024: Early Adjuvant Chemotherapy Improves Survival in Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
(UroToday.com) The 2024 South Central AUA annual meeting included a session on bladder cancer, featuring a presentation by Dr. Gal Saffati discussing a systematic review and meta-analysis of early ...
UroToday4d
EAU 2024: Extended Follow-up from CheckMate 274 Including the First Report of Overall Survival Outcomes
(UroToday.com) The 2024 European Association of Urology (EAU) annual meeting featured a game changing session on prime time for adjuvant treatment in locally advanced bladder cancer, and a ...
UroToday5d
SCS AUA 2024: Can the PSMA PET SUVmax Predict High Risk Pathology and High Risk Disease? A Single Center Prospective Disease
(UroToday.com) The 2024 South Central AUA annual meeting included the fellow essay podium presentation competition, featuring a presentation by Dr. Jorge Alcacio-Mendoza discussing whether PSMA PET ...
UroToday5d
SCS AUA 2024: Elucidating the Response Rates to Additional BCG: Implications for Clinical Trial Design
(UroToday.com) The 2024 South Central AUA annual meeting included the Sushil Lacy manuscript competition, featuring a presentation by Dr. Amanda Myers discussing the elucidation of response rates to ...
UroToday5d
ESMO 2024: Tumor Suppressor Gene Signature Predicts Early Progression in mHSPC Patients
There were 137 patients included in this study with a median age of 71.8 years (range 50.1-92.8). There were 77.4% of patients that presented de novo stage IV, 16.1% with visceral metastasis, and 53.3 ...
UroToday5d
Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors.
The Case A 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation ...
UroToday5d
Assessing racial differences in time to subsequent treatment following androgen deprivation therapy among Veterans with prostate cancer.
Background For metastatic and certain advanced prostate cancer (PC), guidelines support intensified androgen deprivation therapy (ADT) as first-line (1L) systemic treatment for improved outcomes.
UroToday5d
Prototol for the Prospective Sample Collection for Cancer of Bladder (ProCaB) Trial by the Cancer of the Bladder Leuven (CaBLe) Consortium.
Non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease categorized as low, intermediate, high, or very high risk, for which recurrence and progression rates and thus management ...